Keep Up with the Latest Clinical Updates

Clinical and scientific leaders from around the country provide their views on the latest clinical data regarding head lice therapy and management.

 

Dr. Clark is a Professor of Environmental Toxicology and Chemistry and Director of the Massachusetts Pesticide Analysis Laboratory at the Veterinary & Animal Sciences Department, and at the University of Massachusetts, Amherst.

Dr. Shirley Gordon, Director of the Head Lice Treatment and Prevention Project, talks about the negative impact head lice can have on mental health.

A concept analysis demonstrating how stigmas result from head lice infestations is also available from Dr. Sheila Hurst, Assistant Professor of ADN Nursing at North Idaho College.

 

Dr. Shirley Gordon is a Professor at Florida Atlantic University, Christine E. Lynn College of Nursing, and Director of the Head Lice Treatment and Prevention Project.

 

Dr. Christopher Belcher: President, Infectious Disease of Indiana and Director of Pediatric Infectious Diseases, Peyton Manning Children’s Hospital.

Primary Studies and Systematic Review Articles

Gellatly KJ, Krim S, Palenchar DJ, et al. Expansion of the Knockdown Resistance Frequency Map for Human Head Lice (Phthiraptera: Pediculidae) in the United States Using Quantitative Sequencing. J Med Entomol. 2016;53(3):653-659.

Yoon KS, Clark JM, et al. Knockdown Resistance Allele Frequencies in North American Head Louse (Anoplura: Pediculidae) Populations. Med Entomol. 2014;51(2):450-457.

Hodgdon HE, Yoon KS, Previte DG, et al. Determination of knockdown resistance allele frequencies in global head louse populations using the serial invasive signal amplification reaction. Pest Manag Sci. 2010;66(9):1031-1040.

Yoon KS, Gao JR, Lee SH, Clark JM, Brown L, Taplin D. Permethrin-resistant human head lice, Pediculus capitis, and their treatment. Archives of Dermatology. 2003;139(8):994-1000.

Indication
Spinosad Topical Suspension 0.9% is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Spinosad Topical Suspension 0.9% should be used in the context of an overall lice management program:
• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Important Safety Information
Spinosad Topical Suspension 0.9% contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Reference(s)
  1. IQVIA: May 5, 2020

SPN-RRW3-001

Important Safety Information

Indication
Spinosad Topical Suspension 0.9% is a pediculicide indicated for the topical treatment of head lice infestations in patients six (6) months of age and older.

Adjunctive Measures
Spinosad Topical Suspension 0.9% should be used in the context of an overall lice management program:
• Wash (in hot water) or dry clean all recently worn clothing, hats, used bedding and towels
• Wash personal care items such as combs, brushes, and hair clips in hot water
• A fine-toothed comb or special nit comb may be used to remove dead lice and nits.

Important Safety Information
Spinosad Topical Suspension 0.9% contains benzyl alcohol and is not recommended for use in neonates and infants below the age of 6 months. Systemic exposure to benzyl alcohol has been associated with serious adverse reactions and death in neonates and low birth-weight infants when administered intravenously. Most common adverse events were: application site redness (3%), eye redness (2%) and application site irritation (1%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.